§ 314.92. Drug products for which abbreviated applications may be submitted.
205 words·~1 min read·
/us/cfr/t21/s§ 314.92·A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
(a)Abbreviated applications are suitable for the following drug products within the limits set forth under § 314.93:
(1)Drug products that are the same as a listed drug. A “listed drug” is defined in § 314.3. For determining the suitability of an abbreviated new drug application, the term “same as” means identical in active ingredient(s), dosage form, strength, route of administration, and conditions of use, except that conditions of use for which approval cannot be granted because of exclusivity or an existing patent may be omitted. If a listed drug has been voluntarily withdrawn from or not offered for sale by its manufacturer, a person who wishes to submit an abbreviated new drug application for the drug shall comply with § 314.122.
(2)[Reserved]
(3)Drug products that have been declared suitable for an abbreviated new drug application submission by FDA through the petition procedures set forth under § 10.30 of this chapter and § 314.93.
(b)FDA will publish in the list listed drugs for which abbreviated applications may be submitted. The list is available from the Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402, 202-783-3238. [57 FR 17983, Apr. 28, 1992, as amended at 64 FR 401, Jan. 5, 1999]
Connections2 cite this
Cited by 2 sections
Citation graph
cites case law
§ 314.92
Drug products for which abbreviated applications may be submitted.
Fed. Reg.×2
Cites 0Cited by 2 across 1 source